Alphabodies have the potential to access an extremely broad target universe, including intracellular targets, by combining the most attractive properties of antibodies and small chemical drugs. This means that they could revolutionise the development of new therapeutics, and transform drug development as we know it today. As a result, the Alphabody platform could potentially generate many novel therapeutics with blockbuster potential.
Furthermore, Alphabodies have the potential to replace the use of antibodies and small molecules in a number of indications, based on a better efficacy, superior side effect profile, or more convenient dosing. These characteristics also mean that Alphabody therapeutics can be developed for a broad range of diseases for which no therapies currently exist.